1. Search Result
Search Result
Results for "

myosin

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

4

Fluorescent Dye

1

Biochemical Assay Reagents

12

Peptides

3

Natural
Products

3

Recombinant Proteins

6

Isotope-Labeled Compounds

10

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152949

    Myosin Neurological Disease
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex .
    Myosin V-IN-1
  • HY-107657
    (+)-Blebbistatin
    1 Publications Verification

    Myosin Others
    (+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective inhibitor of myosin II ATPase .
    (+)-Blebbistatin
  • HY-Y0413

    Diacetyl monoxime; DAM

    Na+/K+ ATPase Myosin Metabolic Disease
    Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca 2+ release .
    Biacetyl monoxime
  • HY-163120

    Myosin Cardiovascular Disease
    Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .
    Myosin-IN-1
  • HY-161608

    Myosin Cardiovascular Disease
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 1
  • HY-161609

    Myosin Cardiovascular Disease
    Myosin modulator 2 (Compound B172) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 2.013, 2.94 and 20.93 μM, respectively. Myosin modulator 2 regulates systolic cardiac performance in Sprague Dawley rats .
    Myosin modulator 2
  • HY-P5998

    Myosin Cancer
    Myosin Light Chain Kinase Substrate (smooth muscle) is a smooth muscle myosin light chain kinase (MLCK) synthetic peptide substrate .
    Myosin Light Chain Kinase Substrate (smooth muscle)
  • HY-159821

    Myosin Cardiovascular Disease
    Ulacamten is a potent cardiac myosin inhibitor .
    Ulacamten
  • HY-123326

    Myosin Infection
    KT5926 is a potent selective myosin light chain kinase inhibitor that inhibits viral primary and secondary transcription and genomic RNA synthesis .
    KT5926
  • HY-128482

    4-Sulfobenzenediazonium

    Others Others
    Diazobenzenesulfonic acid (4-Sulfobenzenediazonium) is an inhibitor of aliostericeffect for myosin ATPase 13 .
    Diazobenzenesulfonic acid
  • HY-139465

    CK-274; CK-3773274

    Myosin Cardiovascular Disease
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM) .
    Aficamten
  • HY-148516

    Myosin Neurological Disease
    MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness .
    MPH-220
  • HY-126913

    ROCK Cancer
    Rhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization .
    Rhodblock 6
  • HY-148799

    Myosin Others
    Sevasemten is an orally active allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten exhibits selectively myosin inhibition with IC50s of ≤10 μM (skeletal), >100 μM (cardiac), respectively. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models .
    Sevasemten
  • HY-16690
    BTS
    2 Publications Verification

    N-Benzyl-p-toluenesulfonamide; N-Tosylbenzylamine

    Myosin Others
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 μM for actin- and Ca 2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers .
    BTS
  • HY-148516A

    Myosin Neurological Disease
    (R)-MPH-220 is the R isomer of MPH-220 (HY-148516). MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness .
    (R)-MPH-220
  • HY-152190

    Myosin Cardiovascular Disease
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB002
  • HY-116420

    ROCK Neurological Disease
    ROCK2-IN-8 (Compound 1) is an orally active ROCK2 inhibitor, with an IC50 of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .
    ROCK2-IN-8
  • HY-100912
    W-7 hydrochloride
    4 Publications Verification

    Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Cancer
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca 2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively . W-7 hydrochloride induces apoptosis and has antitumor activity .
    W-7 hydrochloride
  • HY-152206

    Myosin Neurological Disease
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB062
  • HY-152205

    Myosin Others
    JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM .
    JB061
  • HY-120870

    Myosin Metabolic Disease
    para-Nitroblebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor, usd in the study of the specific role of myosin II in physiological, developmental, and cell biological studies .
    para-Nitroblebbistatin
  • HY-14233
    Omecamtiv mecarbil
    3 Publications Verification

    CK-1827452

    Myosin Cardiovascular Disease
    Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil
  • HY-13441
    (-)-Blebbistatin
    10+ Cited Publications

    Myosin Cardiovascular Disease Cancer
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II .
    (-)-Blebbistatin
  • HY-115669

    Antibiotic A 15104 Y; PClP

    Myosin TGF-β Receptor Cancer
    Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β .
    Pentachloropseudilin
  • HY-100685
    MS-444
    1 Publications Verification

    BE-34776

    Myosin Cancer
    MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
    MS-444
  • HY-109037
    Mavacamten
    5+ Cited Publications

    MYK461; SAR439152

    Myosin Cardiovascular Disease
    Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten
  • HY-14233S

    CK-1827452-d8

    Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Omecamtiv mecarbil-d8 is the deuterium labeled Omecamtiv mecarbil. Omecamtiv mecarbil (CK-1827452) is a selective cardiac myosin activator.
    Omecamtiv mecarbil-d8
  • HY-109128
    Danicamtiv
    1 Publications Verification

    MYK-491

    Myosin Cancer
    Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency .
    Danicamtiv
  • HY-P2162

    Myosin Cancer
    Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK) .
    Kemptamide
  • HY-P1029
    MLCK inhibitor peptide 18
    3 Publications Verification

    Myosin CaMK Autophagy Others
    MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
    MLCK inhibitor peptide 18
  • HY-111474

    Myosin Cardiovascular Disease Neurological Disease
    Para-aminoblebbistatin is a highly water soluble, non-fluorescent and photostable C15 amino-substituted derivative of blebbistatin; inhibits various (myosin II) isoforms both in vitro and in vivo.
    Para-aminoblebbistatin
  • HY-13441G

    Myosin Cardiovascular Disease Cancer
    (-)-Blebbistatin (GMP) is (-)-Blebbistatin (HY-13441) produced by using GMP guidelines. (-)-Blebbistatin (GMP) is a selective inhibitor of the ATPase activity of non-muscle myosin II .
    (-)-Blebbistatin (GMP)
  • HY-114909

    Parasite Infection
    TachypleginA can inhibit the motility of T. gondii by binding directly and covalently to C58 of TgMLC1,thereby causing a decrease in the activity of the parasite's myosin motor .
    TachypleginA
  • HY-W017007SA

    Isotope-Labeled Compounds Endogenous Metabolite Others
    3-Methyl-L-histidine-d3 hydrochloride is the deuterium labeled 3-Methyl-L-histidine hydrochloride. 3-Methyl-L-histidine hydrochloride can be found in actin and myosin and is a derivative of histidine .
    3-Methyl-L-histidine-d3 hydrochloride
  • HY-122200

    JS399-19

    Myosin Fungal Infection
    Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species .
    Phenamacril
  • HY-W017007SB

    Endogenous Metabolite Others
    3-Methyl-D-histidine-d3 hydrochloride is the deuterium labeled 3-Methyl-D-histidine hydrochloride. 3-Methyl-D-histidine hydrochloride can be found in actin and myosin and is a derivative of histidine .
    3-Methyl-D-histidine-d3 hydrochloride
  • HY-109037R

    Myosin Cardiovascular Disease
    Mavacamten (Standard) is the analytical standard of Mavacamten. This product is intended for research and analytical applications. Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten (Standard)
  • HY-13813
    Blebbistatin
    Maximum Cited Publications
    20 Publications Verification

    Myosin Others
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration .
    Blebbistatin
  • HY-P1805

    Calmodulin Neurological Disease
    Calmodulin Binding Peptide 1 is a high affinity (pM) CaM-binding peptide derived from smooth muscle myosin light-chain kinase (MLCK peptide), which strongly inhibits IP3-induced Ca 2+ release .
    Calmodulin Binding Peptide 1
  • HY-119038

    Others Cardiovascular Disease
    ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury .
    ML-7
  • HY-126236

    Thyroid Hormone Receptor Cardiovascular Disease Endocrinology
    3,5-Diiodothyropropionic acid is a thyroid hormone analog, induces α-myosin heavy chain mRNA expression, binds to thyroid hormone receptor (TR), with Ka of 2.40 and 4.06 M -1 for TRα1 and TRβ1, respectively .
    3,5-Diiodothyropropionic acid
  • HY-109037S2

    MYK461-d1; SAR439152-d1

    Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Mavacamten-d1 (MYK461-d1; SAR439152-d1) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d1
  • HY-109037S3

    MYK461-d5; SAR439152-d5

    Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Mavacamten-d5 (MYK461-d5; SAR439152-d5) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d5
  • HY-109037S

    MYK461-d6; SAR439152-d6

    Isotope-Labeled Compounds Myosin Cardiovascular Disease
    Mavacamten-d6 (MYK461-d6; SAR439152-d6) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d6
  • HY-E70231

    Others Cardiovascular Disease
    Defibrase, deinagkistrodonacutus is a proteolytic enzyme extraction of Agkistrodon halys venom. Defibrase can be used for degradation of fibrinogen. Defibrase can exacerbate myosin-induced EAM (experimental autoimmune myositis). Defibrase can be used for degradation of fibrinogen. Defibrase is commonly used for research of acute ischemic cerebrovascular disease, thromboangiitis obliterans, deep phlebitis and sudden deafness .
    Defibrase, deinagkistrodonacutus
  • HY-120997

    Berbamine p-nitrobenzoate

    Calmodulin Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activity of calmodulin (CaM)-dependent myosin light chain kinase (MLCK), with a Ki of 0.95 μM . E6 Berbamine also shows anti-leukemia activities, with an IC50 of 2.13 μM in K562 cells .
    E6 Berbamine
  • HY-113604

    TGF-β Receptor Cancer
    Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour and phytotoxic activities. PBrP is a reversible and allosteric inhibitor of myosin Va (MyoVa). PBrP also is a potent inhibitor of transforming growth factor-β (TGF-β) activity. PBrP can be used for the research of fibrotic diseases and cancer .
    Pentabromopseudilin
  • HY-100932
    ML-9
    4 Publications Verification

    Myosin Cancer
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54?μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
    ML-9
  • HY-125957

    PKA Casein Kinase CaMK PKC Others
    A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 μM), casein kinase II (Ki=5.1 μM) and myosin light chain kinase (MLCK) (Ki=7.4 μM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 μM and 80 μM, respectively .
    A-3 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: